<SEC-DOCUMENT>0001193125-24-255207.txt : 20241112
<SEC-HEADER>0001193125-24-255207.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112081912
ACCESSION NUMBER:		0001193125-24-255207
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279773
		FILM NUMBER:		241443670

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d853396d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR> Registration No. 333-279773 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
May&nbsp;29, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>88,500,000 American Depositary Shares representing 885,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g853396g1112031404620.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May&nbsp;29, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on November&nbsp;12, 2024 (the &#147;November 12, 2024 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have
attached the November&nbsp;12, 2024 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates
and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be
read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On November&nbsp;11, 2024, the last reported sale
price of the ADSs on Nasdaq was $6.78 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is November&nbsp;12, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;&#8195;</FONT> Form <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;12, 2024, Kazia Therapeutics Limited (the &#147;Company&#148;) announced that it received a written notification
(the &#147;Notification Letter&#148;) from the Nasdaq Stock Market, LLC (&#147;Nasdaq&#148;) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule
5550(a)(2) (the &#147;Minimum Bid Price Requirement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Notification Letter confirmed that the closing bid price of the
Company&#146;s American Depositary Shares (the &#147;ADSs&#148;), representing 100 ordinary shares of the Company per ADS, on Nasdaq Capital Market has been at $1.00 per ADS or greater for 10 consecutive business days from October&nbsp;28, 2024 to
November&nbsp;8, 2024 and that the Company has regained compliance with the Minimum Bid Price Requirement.<B> </B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November&nbsp;12, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g853396g1112031404620.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g853396g1112031404620.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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+M%)10 M%)10!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
